Among people known as ‘lichens’, ‘alopecia areata’ forces those who struggle with the disease mentally because of the appearance it causes. However, a study conducted in the US, the results of which were recently shared, caused great excitement. The researchers said that a new drug that will solve baldness caused by a skin disease is an “important milestone”.
The exact cause of the skin disease is unknown. According to experts, the main source of the disease is autoimmune causes. Autoimmune diseases occur when the body considers its own cells and tissues to be foreign. In other words, the immune system attacks a person’s own cells. In skin diseases, immune cells attack hair follicles, stop hair growth and cause hair loss. Some may experience regional baldness due to molting, while others may grow hair over time. No matter what is done, however, there are also cases that result in complete baldness.
Here, the pharmaceutical company Concert Pharma also examined 706 people with moderate to severe alopecia areata in a study conducted in the USA. While some volunteers divided into 3 groups were given an 8 mg pill containing a CTP-543 inhibitor twice a day, some were given a 12 mg pill containing a CTP-543 inhibitor twice a day. The second group was asked to drink a placebo (a dummy medicine used in the studies).
80 HAIR PERCENTAGE AGAINST
A statistically significant proportion of volunteers in both groups who took the pills had greater hair follicle rejuvenation compared to those who took placebo. In fact, it has been observed that at least 80 percent of their hair has regrown after using the drug in a very large proportion of study participants. It was a pleasure to see such a result in the final phase of clinical trials of a drug for alopecia areata containing a CTP-543 inhibitor. A dermatologist from the Yale University School of Medicine who was part of the study team. Brett King said:
“This study represents an important milestone in the development of new treatments for alopecia areata. I am pleased to have had such positive results from the first phase 3 study with CTP-543. CTP-543 has the potential to be the best treatment for the long-overlooked, challenging alopecia areata.” owner.”
Chris Rock’s moderating jokes about the baldness of Will Smith’s wife, Jada Pinkett Smith, sparked tension at the Oscars in 2022. Will Smith, who was smiling in the face of the jokes, stood up as the dose of jokes increased and slapped Chris Rock in a live broadcast. It turned out that the reason Jada Pinkett Smith didn’t go bald was a skin condition.
“IT WILL BE CLEAR IN THE THIRD QUARTER OF 2022”
Dermatology Specialist Dr. Nezih Karaca He emphasized that this study, which was carried out in Turkey, was not carried out because of the baldness that everyone could see, but only because of the baldness that developed as a result of the skin disease, and made the following statement:
“Phase 3 of this study will be completed in the third quarter of 2022, the study is not yet complete. However, the study’s data to date show that: There is a great improvement, especially in areas where hair loss is evident in 8 weeks.” Irregular hair is observed at this time, especially in alopecia areata. CTP-543 is reported to potentially provide a good hair loss result. However, we will speak much more clearly after receiving the results of the phase 3 study in the third quarter of 2022. The results so far are promising. The treatment of skin disease is difficult, stubborn and complex. Development is therefore promising for cases that have not responded to treatment tested. Sometimes we need new treatment methods in the difficult CTP-543 is one of them. “